La Iniciativa per Medicines Innovadores 2 (IMI 2) considera la publicació els següents tòpics:
• Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• Genome-environment interactions in inflammatory skin disease
• The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• Mitochondrial dysfunction in neurodegeneration
• Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
• A sustainable European induced pluripotent stem cell platform
• Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
• Human tumour microenvironment immunoprofiling
• CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
• Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• Federated and privacy-preserving machine learning in support of drug discovery
• Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Descripció detallada per cada tòpic proposat (http://www.imi.europa.eu/content/future-topics).